Design Therapeutics Shares Jump After Four-Week RESTORE-FA Readout Shows Biological and Clinical Signals
Design Therapeutics (NASDAQ:DSGN) climbed 27% after reporting four-week data from its RESTORE-FA study of DT-216P2 in Friedreich ataxia. The investigational therapy produced dose-dependent improvements on multiple clinical measures, increases in endogenous frataxin mRNA and protein, and was generally well tolerated across dose cohorts through four …